Japanese-Western consensus meeting on biomarkers.

[1]  U. Janssens,et al.  Evaluation of a new, rapid bedside test for quantitative determination of B-type natriuretic peptide. , 2001, Clinical chemistry.

[2]  M. Givertz,et al.  B-type natriuretic peptide and the stressed heart. , 2006, Journal of the American College of Cardiology.

[3]  T. Takano,et al.  Early identification of cardiac events with serum troponin T in patients with unstable angina , 1993, The Lancet.

[4]  K. Nakao,et al.  Increased Plasma Levels of Brain Natriuretic Peptide in Patients With Acute Myocardial Infarction , 1993, Circulation.

[5]  R. Wuerz,et al.  Effects of prehospital medications on mortality and length of stay in congestive heart failure. , 1992, Annals of emergency medicine.

[6]  A. Cohen-Solal,et al.  Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.

[7]  M. Quiñones,et al.  Comparative cost-effectiveness of B-type natriuretic peptide and echocardiography for predicting outcome in patients with congestive heart failure. , 2006, The American journal of cardiology.

[8]  T. Kanda,et al.  Stretch-induced Hypertrophic Growth of Cardiocytes and Processing of Brain-type Natriuretic Peptide Are Controlled by Proprotein-processing Endoprotease Furin* , 1997, The Journal of Biological Chemistry.

[9]  M. Kinoshita,et al.  Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[10]  Robert Woolard,et al.  Missed Diagnoses of Acute Cardiac Ischemia in the Emergency Department , 2000 .

[11]  N. Minamino,et al.  Natriuretic Peptides in the Cardiovascular System , 2006 .

[12]  H. Morita,et al.  Use of a whole blood rapid panel test for heart-type fatty acid-binding protein in patients with acute chest pain: comparison with rapid troponin T and myoglobin tests. , 2003, The American journal of medicine.

[13]  C. Frampton,et al.  NTproBNP‐guided drug treatment for chronic heart failure: design and methods in the “BATTLESCARRED” trial , 2006, European journal of heart failure.

[14]  Faquan Liang,et al.  Evidence for functional heterogeneity of circulating B-type natriuretic peptide. , 2007, Journal of the American College of Cardiology.

[15]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[16]  A. Jaffe,et al.  Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. , 2008, Clinical chemistry.

[17]  N. S. Pollitt,et al.  The precursor to B-type natriuretic peptide is an O-linked glycoprotein. , 2006, Archives of biochemistry and biophysics.

[18]  Peter Buser,et al.  BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. , 2009, JAMA.

[19]  T. Takano,et al.  Difference in elevation of N-terminal pro-BNP and conventional cardiac markers between patients with ST elevation vs non-ST elevation acute coronary syndrome. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[20]  B. Sarg,et al.  Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. , 2008, Clinical chemistry.

[21]  W. Gibler,et al.  Outcomes associated with small changes in normal-range cardiac markers. , 2011, The American journal of emergency medicine.

[22]  W. Peacock,et al.  Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. , 2008, Journal of the American College of Cardiology.

[23]  K. Kugiyama,et al.  Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.

[24]  Tobias Reichlin,et al.  Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. , 2009, The New England journal of medicine.

[25]  A. G. Semenov,et al.  Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. , 2009, Clinical chemistry.

[26]  Fred S Apple,et al.  Immunodetection of glycosylated NT-proBNP circulating in human blood. , 2008, Clinical chemistry.

[27]  L. Wallentin,et al.  Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. , 2005, Journal of the American College of Cardiology.

[28]  H. White,et al.  N-Terminal Pro–B-Type Natriuretic Peptide Levels for Dynamic Risk Stratification of Patients With Acute Coronary Syndromes , 2004, Circulation.

[29]  K. Nakao,et al.  Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-term follow-up analysis. , 2004, Circulation.

[30]  C. Phillips,et al.  Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.

[31]  R. Doughty,et al.  Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 1999, Circulation.

[32]  A. G. Semenov,et al.  The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. , 2007, Clinical chemistry.

[33]  T. Inomata,et al.  Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure. , 2008, Journal of the American College of Cardiology.

[34]  R. Troughton,et al.  NT‐proBNP in heart failure: therapy decisions and monitoring , 2004, European journal of heart failure.

[35]  J. Alpert,et al.  Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction , 2008 .

[36]  L. Fisher,et al.  Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.

[37]  Y. Kihara,et al.  B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. , 2006, Journal of the American College of Cardiology.

[38]  R. Fitzgerald,et al.  Pro-B-type natriuretic peptide levels in acute decompensated heart failure. , 2008, Journal of the American College of Cardiology.

[39]  Stefan Blankenberg,et al.  Sensitive troponin I assay in early diagnosis of acute myocardial infarction. , 2009, The New England journal of medicine.

[40]  T. Takano,et al.  Pathophysiological analysis of serum troponin T release kinetics in evolving ischemic myocardial injury. , 1996, Japanese circulation journal.

[41]  C. Granier,et al.  Assay for measurement of intact B-type natriuretic peptide prohormone in blood. , 2006, Clinical chemistry.

[42]  W. Gibler,et al.  National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. , 1999, Clinical chemistry.

[43]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[44]  H. Itoh,et al.  Brain natriuretic peptide is a novel cardiac hormone. , 1989, Biochemical and biophysical research communications.

[45]  S. Yusuf,et al.  Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction , 1995 .

[46]  T. Ishimitsu,et al.  Diversity of molecular forms of plasma brain natriuretic peptide in heart failure—different proBNP-108 to BNP-32 ratios in atrial and ventricular overload , 2009, Heart.

[47]  P. Shekelle,et al.  Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. , 2004, Journal of the American College of Cardiology.

[48]  Michihisa Jougasaki,et al.  Different Secretion Patterns of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Patients With Congestive Heart Failure , 1993, Circulation.

[49]  N. Maeda,et al.  The role of natriuretic peptides in cardioprotection. , 2006, Cardiovascular research.

[50]  G. Fonarow,et al.  Early vasoactive drugs improve heart failure outcomes. , 2009, Congestive heart failure.

[51]  K. Nakao,et al.  B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. , 2002, The American journal of medicine.

[52]  Jeroen J. Bax,et al.  Universal definition of myocardial infarction. , 2007 .

[53]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[54]  K. Inouye,et al.  Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. , 1991, The Journal of clinical investigation.